The global non-injectable insulin market size was USD 1.47 billion in 2023, calculated at USD 1.66 billion in 2024 and is expected to reach around USD 5.63 billion by 2034. The market is expanding at a solid CAGR of 12.99% over the forecast period 2024 to 2034.
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Non-Injectable Insulin Market
5.1. COVID-19 Landscape: Non-Injectable Insulin Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Non-Injectable Insulin Market, By Product
8.1. Non-Injectable Insulin Market Revenue and Volume, by Product, 2024-2034
8.1.1. Pills
8.1.1.1. Market Revenue and Volume Forecast (2021-2034)
8.1.2. Sprays
8.1.2.1. Market Revenue and Volume Forecast (2021-2034)
8.1.3. Others
8.1.3.1. Market Revenue and Volume Forecast (2021-2034)
Chapter 9. Global Non-Injectable Insulin Market, By Distribution Channel
9.1. Non-Injectable Insulin Market Revenue and Volume, by Distribution Channel, 2024-2034
9.1.1. Hospital Pharmacies
9.1.1.1. Market Revenue and Volume Forecast (2021-2034)
9.1.2. Online Pharmacies
9.1.2.1. Market Revenue and Volume Forecast (2021-2034)
9.1.3. Drug Stores
9.1.3.1. Market Revenue and Volume Forecast (2021-2034)
Chapter 10. Global Non-Injectable Insulin Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.1.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
10.1.3. U.S.
10.1.3.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.1.3.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.1.4.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
10.2. Europe
10.2.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.2.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
10.2.3. UK
10.2.3.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.2.3.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
10.2.4. Germany
10.2.4.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.2.4.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
10.2.5. France
10.2.5.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.2.5.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.2.6.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
10.3. APAC
10.3.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.3.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
10.3.3. India
10.3.3.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.3.3.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
10.3.4. China
10.3.4.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.3.4.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
10.3.5. Japan
10.3.5.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.3.5.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.3.6.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
10.4. MEA
10.4.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.4.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
10.4.3. GCC
10.4.3.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.4.3.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
10.4.4. North Africa
10.4.4.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.4.4.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
10.4.5. South Africa
10.4.5.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.4.5.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.4.6.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
10.5. Latin America
10.5.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.5.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
10.5.3. Brazil
10.5.3.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.5.3.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.5.4.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
Chapter 11. Company Profiles
11.1. Novo Nordisk
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Sanofi
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Eli Lilly
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. MannKind Corporation
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Biocon
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Janssen Pharmaceuticals
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Adocia
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Oramed Pharmaceuticals
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Dance Biopharm
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Medtronic
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample